Welcome to to the Irish Medical Times website
This site is aimed at healthcare professionals.
Are you a healthcare professional?
This site contains information, news and advice for healthcare professionals.
You have informed us that you are not a healthcare professional and therefore we are unable to provide you with access to this site.

May 26, 2015

Treatment of Metastatic Colorectal Cancer

Download PDF INCIDENCE IN IRELAND Colorectal cancer (CRC) is the second most common invasive cancer diagnosed in women (after breast cancer) and in men (after prostate cancer). Approximately 1,031 women and 1,405 men were diagnosed with CRC annually during 2009-2011. 11.5% (in women) and 13.7% (in men) of all invasive cancers (excluding non-melanoma skin cancer) […]

Bisphosphonates and denosumab – Minimising the risk of osteonecrosis of the jaw (ONJ)

The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has completed a periodic review of one of the bisphosphonate medicines, Aclasta (zoledronic acid). Bisphosphonates are used in the treatment of osteoporosis and are associated with a known, small risk of osteonecrosis of the jaw (ONJ). The HPRA has previously communicated on the risk of […]

Hay Fever Policy (Glucocorticosteroid Injections)

Therapeutic Use Exemption (TUE) Committee Policy on Glucocorticosteroid Injections for Hay Fever Depo-Medrone (Methylprednisolone) and Kenalog* (Triamcinolone) administered by intra-muscular injection as treatment for hay fever are prohibited in sport and therefore their use requires the athlete and their physician to strictly adhere to the TUE Policy. The TUE Policy is available at www.irishsportscouncil.ie/tue. Athletes […]

Interchangeable Medicines and Reference Pricing

The Health (Pricing and Supply of Medical Goods) Act 2013 has introduced a system of generic substitution and reference pricing. Under this legislation, interchangeable medicines are defined as those medicines that contain the same active ingredient in the same strength, are in the same pharmaceutical form, and have the same route of administration. Reference pricing […]


Company: Ferring Ireland Ltd. Legal category: GMS. Prescription.  Sport prohibited in competition. Active ingredient: Budesonide 9mg. Description: White, round, biconvex, film-coated, gastro-resistant, prolonged release tablet marked MX9. Presentation: 30, €85.00. Indication: Induction of remission in patients with mild to moderate active ulcerative colitis where 5-ASA treatment is not sufficient. Pharmacology: Budesonide inhibits many inflammatory processes […]

Dacogen ▼

Company: Janssen-Cilag Ltd. Legal category: Prescription. Hospital only. Sport permitted. Active ingredient: Decitabine 50mg. Description: Powder for concentrate for solution for infusion. Presentation: 1 vial, €1110.00. Indications: Treatment of patients with newly diagnosed de novo or secondary acute myeloid leukaemia, who are not candidates for standard induction chemotherapy. Pharmacology: Decitabine is a cytidine deoxynucleoside analogue […]

Imbruvica ▼

Company: Janssen-Cilag Ltd. Legal category: Prescription. Sport permitted. Active ingredient: Ibrutinib 140mg. Description: White opaque, hard capsule marked ibr 140mg. Presentation: Price pending reimbursement. Indications: Treatment of relapsed or refractory mantle cell lymphoma (MCL). Treatment of patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in […]

Kapake 15/500mg

Company: Galen Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredients: Codeine phosphate/paracetamol 15/500mg. Description: White, oblong, tablet marked K1 on both sides of scoreline. Presentation: 100, €7.80. Indication: Relief of moderate pain. Pharmacology: Paracetamol has analgesic and antipyretic effects. The mechanism of action is unclear, although it is believed to exert its action by […]

Noxafil IV

Company: MSD Ireland (Human Health) Ltd. Legal category: Prescription. Hospital. Sport permitted. Active ingredient: Posaconazole 300mg. Description: Concentrate for solution for infusion. Presentation: 1 vial, €452.37. Indications: Treatment of invasive aspergillosis, fusariosis, chromoblastomycosis, mycetoma, coccidioidomycosis, in adults with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of […]

Plegridy ▼

Company: Biogen Idec (Ireland) Ltd. Legal category: Prescription. High tech. Sport permitted. Active ingredient: Peginterferon beta-1a 63mcg/0.5ml, 94mcg/0.5ml, 125mcg/0.5ml. Description: Solution for injection in pre-filled pens labelled orange, blue or grey, respectively. Presentation: Initiation pack: 1 x 63mcg and 1 x 94mcg pre-filled pen, €884.00. Maintenance pack: 125mcg-2 pre-filled pens, €884.00. Indication: Treatment of relapsing […]

Next Page »